GlassScriptPhysician profile
Lisa M Kopas
NPI 1174795157
$120,179.28
in general payments reported to CMS, 2019-2025
18 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $17K · 2021: $13K · 2022: $22K · 2023: $19K · 2024: $19K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $6,984 · Food and Beverage: $2,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,040.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,610.00 |
| Travel and Lodging | $6,983.75 |
| Food and Beverage | $2,379.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $105,056.38 | 2019-2025 | Ofev, Jascayd |
| Pulmonx Corporation | $8,786.61 | 2019-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Intuitive Surgical, INC. | $4,442.33 | 2019-2025 | Da Vinci Sp |
| Ethicon INC. | $440.19 | 2020 | |
| Boston Scientific Corporation | $381.99 | 2019-2022 | |
| Olympus America INC. | $196.13 | 2021-2022 | |
| Glaxosmithkline, LLC. | $195.56 | 2024-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $144.32 | 2022 | |
| Inspire Medical Systems, INC. | $137.08 | 2023-2024 | Inspire |
| Electromed, INC. | $104.37 | 2023-2024 | Smartvest |
| Genzyme Corporation | $95.79 | 2023-2025 | |
| Insmed, INC. | $76.57 | 2022-2025 | Brinsupri, Arikayce |
| Olympus Corporation of The Americas | $41.66 | 2019 | |
| Pfizer INC. | $35.06 | 2022-2023 | |
| United Therapeutics Corporation | $25.83 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $19.41 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Kopas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.